A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.
Also called NCT07662109
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,000 participants
- Sponsor
- Registry
-
NCT07662109 -
2025-523941-81-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Brazil, China, Czechia, Denmark, Germany, Greece, Hungary, India, Japan, Malaysia, Mexico, Poland, Puerto Rico, Slovakia, South Africa, South Korea, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom, Vietnam
- Registry status
- Recruiting
Technical summary
Registry record NCT07662109. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-06 (actual); primary completion 2028-07-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
- Acronym
- Eluminate-5
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Elecoglipron
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Elecoglipron-matched placebo
- Intervention (Drug)
- Dapagliflozin-matched placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct07662109- Content hash
2e5e3bad83a0767b37e66197dda8e1f18429cd7db9f17be72d13cc3300c98831